4D Molecular Therapeutics, Inc. FDMT
Set alert
11.37 USD -0.53 -4.45%
At close
11.26 -0.11 -0.97%
Pre-market · Nov 3, 5:23 AM ET
11.16 Day range 12.06
6.96 52-week range 16.93
- YTD
- +51.60%
- 1 year
- +1.34%
- Open
- 11.88
- Prev close
- 11.90
- Mkt cap
- 628.13M
- Vol
- 734.78K
- Avg vol
- 1.01M
- EPS
- -2.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.16
- High
- 12.06
- Forward P/E
- -1.79
- Beta
- 0.00
- Short ratio
- 9.86
- Inst. own
- 115.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 7.82
- 200-d avg
- 17.94
- 1y target
- 42.64
Analyst view
Consensus: buy
Buy
Price target (mean) 42.64 +275.0% upside
Now 11.37
- Target (low)
- 8.00
- Target (mean)
- 42.64
- Target (high)
- 82.00
Ratings (0m) 12 10 buy · 1 hold · 1 sell
- Strong buy5
- Buy5
- Hold1
- Sell1
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 12
- 2 months ago 11
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.8309 | -1.16 – -0.57 | -0.77 | -7.9% | 2.20M | +11682.5% | 10 |
| Next quarter | -0.8175 | -0.96 – -0.66 | -0.66 | -23.9% | 176.00K | +528.6% | 4 |
| Current year | -2.92 | -3.28 – -2.65 | -2.58 | -13.0% | 1.38M | -93.3% | 11 |
| Next year | -3.56 | -4.18 – -2.83 | -2.92 | -22.0% | 3.65M | +163.9% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | B of A Securities | Maintained | Buy | Buy |
| Nov 21, 2024 | Morgan Stanley | Initiated | — | Underweight |
| Nov 14, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 14, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 23, 2024 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Sep 19, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Sep 19, 2024 | Leerink Partners | Reiterated | Outperform | Outperform |
| Sep 19, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Aug 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 22, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Jul 18, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Jul 17, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Jun 26, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Jun 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 15, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 15, 2024 | Barclays | Initiated | — | Overweight |
| Apr 1, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Apr 1, 2024 | Jefferies | Maintained | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 5, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Feb 5, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 29, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Oct 24, 2023 | Cantor Fitzgerald | Initiated | — | Overweight |
| Aug 11, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| Aug 10, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 31, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 11, 2023 | Chardan Capital | Maintained | Buy | Buy |